Heart Attack - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
47 Pages - GMD12058
$2,000.00

Summary

Global Markets Direct’s, ‘Heart Attack - Pipeline Review, H1 2014’, provides an overview of the Heart Attack’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Heart Attack, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Heart Attack and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Heart Attack
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Heart Attack and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Heart Attack products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Heart Attack pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Heart Attack
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Heart Attack pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heart Attack Overview 6
Therapeutics Development 7
Pipeline Products for Heart Attack - Overview 7
Pipeline Products for Heart Attack - Comparative Analysis 8
Heart Attack - Therapeutics under Development by Companies 9
Heart Attack - Therapeutics under Investigation by Universities/Institutes 11
Heart Attack - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Heart Attack - Products under Development by Companies 14
Heart Attack - Products under Investigation by Universities/Institutes 15
Heart Attack - Companies Involved in Therapeutics Development 16
Merck & Co., Inc. 16
Lacer, S.A. 17
Lanthio Pharma B.V. 18
Heart Attack - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
vorapaxar sulfate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AB-002 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LA-8045 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs to Inhibit Myosin for Cardiovascular Disorders - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drugs to Inhibit PDE5 for Heart Attack and Cardiac Injury - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
meclizine hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Peptide Targeting Apelin Receptor - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C3aR Agonist Peptides - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Heart Attack - Recent Pipeline Updates 39
Heart Attack - Dormant Projects 41
Heart Attack - Product Development Milestones 42
Featured News & Press Releases 42
Dec 26, 2013: AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR 42
Dec 23, 2013: Heart Disease Therapy Cleared for Phase 2 Clinical Trial to be Funded by Stem Cell Agency 42
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 43
Aug 06, 2013: Athersys Announces Grant to Support Clinical Advancement of Its MultiStem Regenerative Medicine Program for Heart Attack Patients 43
Mar 11, 2013: Roche's Inclacumab Shows Efficacy In Reducing Heart Damages During Artery Clearing Angioplasty Procedures 44
Nov 29, 2012: AstraZeneca Wins Chinese Approval For New Heart Drug Brilinta 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Heart Attack, H1 2014 7
Number of Products under Development for Heart Attack - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Heart Attack - Pipeline by Merck & Co., Inc., H1 2014 16
Heart Attack - Pipeline by Lacer, S.A., H1 2014 17
Heart Attack - Pipeline by Lanthio Pharma B.V., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Heart Attack Therapeutics - Recent Pipeline Updates, H1 2014 39
Heart Attack - Dormant Projects, H1 2014 41

List of Figures
Number of Products under Development for Heart Attack, H1 2014 7
Number of Products under Development for Heart Attack - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax